Form 4: Adaptimmune Therapeutics CEO Adrian Rawcliffe Sells Shares to Cover Tax Obligations
SEC Form 4
Adaptimmune Therapeutics' CEO, Adrian Rawcliffe, sold American Depositary Shares (ADSs) to cover tax obligations related to the exercise of vested RSU-style share options.
Summary
- Adrian Rawcliffe, CEO of Adaptimmune Therapeutics PLC, executed sales of American Depositary Shares (ADSs) on January 13 and 15, 2025.
- These transactions were part of a 'Sell to Cover' exercise to satisfy tax withholding obligations and associated sale costs related to the vesting and exercise of RSU-style share options.
- The sales occurred at weighted average prices of $0.5879 and $0.5748 per ADS.
- The ADSs represent ordinary shares of Adaptimmune Therapeutics, with each ADS representing six ordinary shares.
- Following these transactions, Rawcliffe continues to hold 265,806 ADSs and RSU-style options and other options covering an aggregate of 34,888,854 ordinary shares of the Issuer.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't convey strong positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership. It doesn't necessarily reflect a change in the company's outlook or performance but provides transparency into executive stock transactions.
Key Dates
| Date | Description |
|---|---|
| 01/11/2021 | Date of grant of RSU-style share option covering ordinary shares of the Issuer. |
| 01/12/2022 | Date of grant of RSU-style share option covering ordinary shares of the Issuer. |
| 01/15/2024 | Date of grant of RSU-style share option covering ordinary shares of the Issuer. |
| 01/13/2025 | Date of ADS sale transactions. |
| 01/15/2025 | Date of ADS sale transactions. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.